查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
生育藥物市場規模份額和趨勢分析報告:按藥物(促性腺激素,芳香□抑製劑,SERM,多巴胺激動劑),用途(男性,女性),分銷渠道,地區,細分市場預測2023～2030
市場調查報告書
商品編碼
1178624

生育藥物市場規模份額和趨勢分析報告:按藥物(促性腺激素,芳香□抑製劑,SERM,多巴胺激動劑),用途(男性,女性),分銷渠道,地區,細分市場預測2023～2030

Infertility Drugs Market Size, Share & Trends Analysis Report By Drug Class (Gonadotropins, Aromatase Inhibitors, SERMs, Dopamine Agonists) By End-user (Men, Women), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10個工作天內

價格

生育藥物市場的增長和趨勢

根據 Grand View Research, Inc. 的最新報告，2023 年至 2030 年，全球生育藥物市場預計將以 6.1% 的複合年增長率增長，2030 年將達到 56 億美元。市場已經飽和，新進入者的機會很少。Merck & Co. Inc.、Ferring BV 和 Organon 集團公司佔據了該市場的大部分市場份額。因此，藥企紛紛著力開發促性腺激素生物類似藥，以開拓市場。例如，齊魯製藥重點研發重組人促卵泡激素QL1012，目前正在進行3期臨床試驗。成功完成臨床試驗並隨後上市有望引領市場。

公共和私人機構越來越多地幫助不孕症患者，預計將對生育治療市場的增長產生積極影響。例如，法國政府於2022年3月出台了體外受精法，允許單身女性和同性伴侶在該國的國家醫療體系下接受免費治療。

同樣在 2022 年 11 月，沙特健康保險委員會進行了一項關於將藥物納入醫療保險範圍的研究。這項研究的成功和藥物的報銷範圍將改善患者獲得治療的機會，隨後，預計在預測期內對該藥物的需求將會增加。

患者和醫生對疾病和可用藥物的認識不斷提高，預計將增加市場的目標人群。例如，2021 年 9 月，Mubadala Health 和 United Eastern Medical Services (UEMedical) 將在迪拜推出“第三方”，旨在提高醫生和患者對這種疾病治療進展及其益處的認識。加上中東不孕症會議。

此外，由於政府努力應對少子化和促進生育，對藥物的需求可能會增加。例如，2022 年 8 月，韓國政府宣布了一項規定，為每個新生兒的家庭每月支付 740 美元，旨在解決該國出生率下降的問題並鼓勵更多的生育。

生育藥物市場報告要點

按藥物類別劃分，促性腺激素部分預計將在 2022 年佔據最大的市場份額，並在預測期內增長最快。這是由於市場上有 FDA 批准的用於治療不孕症的促性腺激素。

從最終用途來看，由於 PCOS、HPV 相關陰道癌和子宮肌瘤等女性疾病發病率上升，2022 年女性市場將主導生育市場。2022 年 4 月，一項隊列研究宣布，約 1.5% 的 20-49 歲法國女性將被診斷患有不孕症。

2022 年的生育藥物市場由醫院藥房板塊主導。這種增長可能是由於全球範圍內因診斷和治療這種疾病而入院的人數增加。

北美在 2022 年主導了全球市場，原因包括醫療保健專業人員對不孕症的認識提高、藥物供應以及疾病流行率上升等因素。

目錄

第一章 調查方法和範圍

  • 市場細分和範圍
    • 段範圍
    • 區域範圍
  • 調查方法
  • 信息採購
    • 購買的數據庫：
    • GVR 內部數據庫
    • 次要信息
    • 初步調查
    • 第一次調查的內容
  • 信息或數據分析
    • 數據分析模型
  • 市場製定和驗證
  • 型號詳情
    • 商品流向分析
      • 方法：產品流方法
  • 調查假設
  • 二級信息列表
  • 縮略語表
  • 目的

第二章執行摘要

  • 市場快照
  • 段快照
  • 爭用快照

3 生育藥物：市場變量、趨勢和範圍

  • 市場系列展望
    • 女性健康市場
  • 繪製滲透率和增長前景
  • 監管狀況
  • 市場動態
  • 市場驅動力分析
    • 增加不孕負擔
    • 存在強大的產品線
    • 增加不孕不育研究和開發的資金
  • 市場約束因素分析
    • 不合作的政府對生育藥物的監管
  • PESTEL 分析
  • 行業分析——波特五力
  • 管道分析

4 生育藥物市場：細分分析，按藥物類別，2018-2030 年（百萬美元）

  • 生育藥物市場：藥物類別的變化分析
  • 促性腺激素
    • 芳香□抑製劑
    • 選擇性雌激素受體調節劑 (SERM)
    • 多巴胺激動劑
    • 其他

5 生育藥物市場：細分分析，按分銷渠道，2018-2030 年（百萬美元）

  • 生育藥物市場：分銷渠道波動分析
  • 醫院藥房
  • 專業和零售藥店
  • 網上藥店

6. 生育藥物市場：細分分析，按最終用途，2018-2030 年（百萬美元）

  • 生育藥物市場：最終用戶差異分析
  • 男性
  • 女士

第七章生育藥物市場：區域估計和趨勢分析

  • 北美
    • SWOT分析：
    • 美國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 加拿大
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
  • 歐洲
    • SWOT分析：
    • 英國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
      • 處方和配藥場景
    • 德國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 法國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 意大利
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 西班牙
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 丹麥
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 瑞典
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 挪威
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
  • 亞太地區
    • SWOT分析：
    • 日本
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
      • 處方和配藥場景
    • 中國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 印度
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 澳大利亞
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 韓國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 泰國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
  • 拉丁美洲
    • SWOT分析：
    • 巴西
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
      • 處方和配藥場景
    • 墨西哥
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 阿根廷
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
  • 中東和非洲 (MEA)
    • SWOT分析：
    • 南非
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
      • 處方和配藥場景
    • 沙特阿拉伯
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 阿拉伯聯合酋長國
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景
    • 科威特
      • 主要國家動態
      • 目標疾病的患病率
      • 競爭情景
      • 監管框架
      • 贖回場景

8 生育藥物市場：競爭分析

  • 主要市場進入者的最新發展和影響分析
    • 新產品發布
    • 併購
    • 許可協議
    • 會議和活動
  • 公司分類
    • 創新者
    • 市場領導者
  • 供應商情況
    • 主要經銷商及渠道合作夥伴名單
    • 主要客戶
  • 上市公司
    • 2021 年主要參與者的市場份額分析
    • 公司市場分析
    • 熱圖分析
    • 競爭儀錶盤分析
      • 市場差異化因素
  • 民營企業
    • 主要初創企業名單
    • 區域網絡圖
  • 公司簡介
    • Bayer AG
    • 公司簡介
    • 財務績效
    • 產品對標
    • 戰略舉措
  • Novartis AG
    • 公司簡介
    • 財務績效
    • 產品基準
    • 戰略舉措
  • Merck
    • 公司簡介
    • 財務績效
    • 產品基準
    • 戰略舉措
  • Ferring BV
    • 公司簡介
    • 財務績效
    • 產品基準
    • 戰略舉措
  • Pfizer
    • 公司簡介
    • 財務績效
    • 產品基準
    • 戰略舉措
  • human pharmaceutical
    • 公司簡介
    • 財務績效
    • 產品基準
    • 戰略舉措
  • Teva Pharmaceutical Industries Ltd.
    • 公司簡介
    • 財務績效
    • 產品基準
    • 戰略舉措
  • Sanofi
    • 公司簡介
    • 財務績效
    • 產品基準
    • 戰略舉措
  • Abbott
    • 公司簡介
    • 財務績效
    • 產品基準
    • 戰略舉措
  • Organon Group of Country
    • 公司簡介
    • 產品基準
    • 戰略舉措
Product Code: GVR-4-68040-016-5

Infertility Drugs Market Growth & Trends:

The global infertility drugs market size is expected to reach USD 5.6 billion by 2030 expanding at a CAGR of 6.1% from 2023 to 2030 according to a new report by Grand View Research, Inc. The market seems to be saturated with fewer opportunities for new entrants. The companies including Merck & Co. Inc., Ferring B.V., and Organon group of companies holds majority of market share. Thus, the pharmaceutical companies are focusing on developing biosimilar of gonadotropins for market penetration. For instance, Qilu Pharmaceutical Co., Ltd. focuses on developing QL1012, a recombinant human follicle stimulating hormone which is under phase 3 clinical trial. Successful completion of of trial and subsequent launch is anticipated to drive market.

Increasing initiatives undertaken by public and private organizations to support patients living with infertility are expected to positively contribute to infertility treatment market growth. For instance, in March 2022, the French government introduced new IVF law under which single women and same sex-couple avail treatment free of cost under the country's national healthcare system.

In addition, in November 2022, Saudi Arabia's Health Insurance Council conducted studies with regard to the inclusion of medicines under medical insurance coverage. The successful completion of the study and inclusion of medication under insurance is anticipated to increase patient access to treatment, subsequently, increase demand for medicines over the forecast period.

Rising awareness about disease and its available medicines among patients and physicians is anticipated to increase the target population for the market. For instance, in September 2021, Mubadala Health and United Eastern Medical Services (UEMedical) organized the '3rd HealthPlus Middle East Fertility Conference with an aim to rise awareness about the advancements in the treatment of this conditions and its benefits among physicians and patients in Dubai.

Moreover, there are several initiatives undertaken by the national government worldwide to tackle low fertility rate issues and promote childbirth which may increase the demand for drugs. For instance, in August 2022, the South Korean Government announced a provision for a monthly allowance of USD 740 per new child born in the family with an aim to tackle the low fertility rate in the country and encourage childbirth.

Infertility Drugs Market Report Highlights:

  • By drug class, the gonadotropin segment accounted for the largest share of the market in 2022 and is anticipated to witness fastest growth over the forecast period. This can be attributed to the availability of FDA-approved gonadotropins for infertility conditions in the market
  • Based on end-user, the women segment dominated the infertility drugs market in 2022 owing to the rising incidence of the diseases such as PCOS, HPV associated vaginal cancer, uterine fibroids in women. As per the cohort studies published, in April 2022, approximately 1.5% of all French women aged 20 to 49 years were diagnosed with this condition annually.
  • Hospiatal pharmacy segment dominated the infertility drugs market in 2022. This growth can be attributed to an increase in inpatient visits for the diagnosis and consulation of this condition worldwide
  • North America dominated the global market in 2022 owing to factors such as high awareness among healthcare professionals about infertility conditions, ease of availability of drugs, and an increase in disease prevalence.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment Scope
    • 1.1.2 Regional Scope
    • 1.1.3 Estimates and Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database:
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation and Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach: Commodity Flow Approach
  • 1.7 Research Assumptions
  • 1.8 List of Secondary Sources
  • 1.9 List of Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective 1
    • 1.10.2 Objective 2
    • 1.10.3 Objective 3
    • 1.10.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Snapshot
  • 2.3 Competitive Snapshot

Chapter 3 Infertility Drugs: Market Variables, Trends, and Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Women's Health Market
  • 3.2 Penetration and Growth Prospect Mapping
  • 3.3 Regulatory Landscape
  • 3.4 Market Dynamics
  • 3.5 Market Driver Analysis
    • 3.5.1 Rising burden of infertility
    • 3.5.2 Presence of strong product pipeline
    • 3.5.3 Increasing funding for infertility R&D
  • 3.6 Market Restraint Analysis
    • 3.6.1. Unsupportive Government Regulations for Infertility Drugs
  • 3.7 PESTEL Analysis
  • 3.8 Industry Analysis-Porter's Five Forces
  • 3.9 Pipeline Analysis

Chapter 4 Infertility Drugs Market: Segment Analysis, by Drug Class, 2018 - 2030 (USD Million)

  • 4.1 Infertility Drugs Market: Drug Class Movement Analysis
  • 4.2 Gonadotropins
    • 4.2.1 Gonadotropins Market, 2018 - 2030 (USD Million)
    • 4.2.2 Aromatase Inhibitors
      • 4.2.2.1 Aromatase Inhibitors Market, 2018 - 2030 (USD Million)
    • 4.2.3 Selective Estrogen Receptor Modulators (SERMs)
      • 4.2.3.1 Selective Estrogen Receptor Modulators (SERMs) Market, 2018 - 2030 (USD Million)
    • 4.2.4 Dopamine Agonists
      • 4.2.4.1 Dopamine Agonists Market, 2018 - 2030 (USD Million)
    • 4.2.5 Others
      • 4.2.5.1 Others Market, 2018 - 2030 (USD Million)

Chapter 5 Infertility Drugs Market: Segment Analysis, by Distribution Channel, 2018 - 2030 (USD Million)

  • 5.1 Infertility Drugs Market: Distribution Channel Movement Analysis
  • 5.2 Hospital Pharmacy
    • 5.2.1 Hospital Pharmacy Market, 2018 - 2030 (USD Million)
  • 5.3 Specialty & Retail Pharmacy
    • 5.3.1 Specialty & Retail Pharmacy Market, 2018 - 2030 (USD Million)
  • 5.4 Online Pharmacy
    • 5.4.1 Online Pharmacy Market, 2018 - 2030 (USD Million)

Chapter 6 Infertility Drugs Market: Segment Analysis, by End-User, 2018 - 2030 (USD Million)

  • 6.1 Infertility Drugs Market: End-User Movement Analysis
  • 6.2 Men
    • 6.2.1 Men Market, 2018 - 2030 (USD Million)
  • 6.3 Women
    • 6.3.1 Women Market, 2018 - 2030 (USD Million)

Chapter 7 Infertility Drugs Market: Regional Estimates and Trend Analysis

  • 7.1 North America
    • 7.1.1 SWOT Analysis:
      • 7.1.1.1 North America Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.1.2 U.S.
      • 7.1.2.1 Key Country Dynamics
      • 7.1.2.2 Target Disease Prevalence
      • 7.1.2.3 Competitive Scenario
      • 7.1.2.4 Regulatory Framework
      • 7.1.2.5 Reimbursement Scenario
      • 7.1.2.6 U.S. Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.1.3 Canada
      • 7.1.3.1 Key Country Dynamics
      • 7.1.3.2 Target Disease Prevalence
      • 7.1.3.3 Competitive Scenario
      • 7.1.3.4 Regulatory Framework
      • 7.1.3.5 Reimbursement Scenario
      • 7.1.3.6 Canada Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2 Europe
    • 7.2.1 SWOT Analysis:
      • 7.2.1.1 Europe Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2 UK
      • 7.2.2.1 Key Country Dynamics
      • 7.2.2.2 Target Disease Prevalence
      • 7.2.2.3 Competitive Scenario
      • 7.2.2.4 Regulatory Framework
      • 7.2.2.5 Reimbursement Scenario
      • 7.2.2.6 Prescription and Dispensing Scenario
      • 7.2.2.7 UK Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3 Germany
      • 7.2.3.1 Key Country Dynamics
      • 7.2.3.2 Target Disease Prevalence
      • 7.2.3.3 Competitive Scenario
      • 7.2.3.4 Regulatory Framework
      • 7.2.3.5 Reimbursement Scenario
      • 7.2.3.6 Germany Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4 France
      • 7.2.4.1 Key Country Dynamics
      • 7.2.4.2 Target Disease Prevalence
      • 7.2.4.3 Competitive Scenario
      • 7.2.4.4 Regulatory Framework
      • 7.2.4.5 Reimbursement Scenario
      • 7.2.4.6 France Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.5 Italy
      • 7.2.5.1 Key Country Dynamics
      • 7.2.5.2 Target Disease Prevalence
      • 7.2.5.3 Competitive Scenario
      • 7.2.5.4 Regulatory Framework
      • 7.2.5.5 Reimbursement Scenario
      • 7.2.5.6 Italy Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.6 Spain
      • 7.2.6.1 Key Country Dynamics
      • 7.2.6.2 Target Disease Prevalence
      • 7.2.6.3 Competitive Scenario
      • 7.2.6.4 Regulatory Framework
      • 7.2.6.5 Reimbursement Scenario
      • 7.2.6.6 Spain Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.7 Denmark
      • 7.2.7.1 Key Country Dynamics
      • 7.2.7.2 Target Disease Prevalence
      • 7.2.7.3 Competitive Scenario
      • 7.2.7.4 Regulatory Framework
      • 7.2.7.5 Reimbursement Scenario
      • 7.2.7.6 Denmark Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.8 Sweden
      • 7.2.8.1 Key Country Dynamics
      • 7.2.8.2 Target Disease Prevalence
      • 7.2.8.3 Competitive Scenario
      • 7.2.8.4 Regulatory Framework
      • 7.2.8.5 Reimbursement Scenario
      • 7.2.8.6 Sweden Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.9 Norway
      • 7.2.9.1 Key Country Dynamics
      • 7.2.9.2 Target Disease Prevalence
      • 7.2.9.3 Competitive Scenario
      • 7.2.9.4 Regulatory Framework
      • 7.2.9.5 Reimbursement Scenario
      • 7.2.9.6 Norway Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.9 Rest of Europe Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Asia Pacific
    • 7.3.1 SWOT Analysis:
      • 7.3.1.1 Asia Pacific Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2 Japan
      • 7.3.2.1 Key Country Dynamics
      • 7.3.2.2 Target Disease Prevalence
      • 7.3.2.3 Competitive Scenario
      • 7.3.2.4 Regulatory Framework
      • 7.3.2.5 Reimbursement Scenario
      • 7.3.2.6 Prescription and Dispensing Scenario
      • 7.3.2.7 Japan Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3 China
      • 7.3.3.1 Key Country Dynamics
      • 7.3.3.2 Target Disease Prevalence
      • 7.3.3.3 Competitive Scenario
      • 7.3.3.4 Regulatory Framework
      • 7.3.3.5 Reimbursement Scenario
      • 7.3.3.6 China Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4 India
      • 7.3.4.1 Key Country Dynamics
      • 7.3.4.2 Target Disease Prevalence
      • 7.3.4.3 Competitive Scenario
      • 7.3.4.4 Regulatory Framework
      • 7.3.4.5 Reimbursement Scenario
      • 7.3.4.6 India Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5 Australia
      • 7.3.5.1 Key Country Dynamics
      • 7.3.5.2 Target Disease Prevalence
      • 7.3.5.3 Competitive Scenario
      • 7.3.5.4 Regulatory Framework
      • 7.3.5.5 Reimbursement Scenario
      • 7.3.5.6 Australia Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6 South Korea
      • 7.3.6.1 Key Country Dynamics
      • 7.3.6.2 Target Disease Prevalence
      • 7.3.6.3 Competitive Scenario
      • 7.3.6.4 Regulatory Framework
      • 7.3.6.5 Reimbursement Scenario
      • 7.3.6.6 South Korea Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7 Thailand
      • 7.3.7.1 Key Country Dynamics
      • 7.3.7.2 Target Disease Prevalence
      • 7.3.7.3 Competitive Scenario
      • 7.3.7.4 Regulatory Framework
      • 7.3.7.5 Reimbursement Scenario
      • 7.3.7.6 Thailand Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8 Rest of APAC Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Latin America
    • 7.4.1 SWOT Analysis:
      • 7.4.1.1 Latin America Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2 Brazil
      • 7.4.2.1 Key Country Dynamics
      • 7.4.2.2 Target Disease Prevalence
      • 7.4.2.3 Competitive Scenario
      • 7.4.2.4 Regulatory Framework
      • 7.4.2.5 Reimbursement Scenario
      • 7.4.2.6 Prescription and Dispensing Scenario
      • 7.4.2.7 Brazil Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3 Mexico
      • 7.4.3.1 Key Country Dynamics
      • 7.4.3.2 Target Disease Prevalence
      • 7.4.3.3 Competitive Scenario
      • 7.4.3.4 Regulatory Framework
      • 7.4.3.5 Reimbursement Scenario
      • 7.4.3.6 Mexico Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4 Argentina
      • 7.4.4.1 Key Country Dynamics
      • 7.4.4.2 Target Disease Prevalence
      • 7.4.4.3 Competitive Scenario
      • 7.4.4.4 Regulatory Framework
      • 7.4.4.5 Reimbursement Scenario
      • 7.4.4.6 Argentina Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. Rest of Latin America Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Middle East & Africa (MEA)
    • 7.5.1 SWOT Analysis:
      • 7.5.1.1 MEA Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2 South Africa
      • 7.5.2.1 Key Country Dynamics
      • 7.5.2.2 Target Disease Prevalence
      • 7.5.2.3 Competitive Scenario
      • 7.5.2.4 Regulatory Framework
      • 7.5.2.5 Reimbursement Scenario
      • 7.5.2.6 Prescription and Dispensing Scenario
      • 7.5.2.7 South Africa Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3 Saudi Arabia
      • 7.5.3.1 Key Country Dynamics
      • 7.5.3.2 Target Disease Prevalence
      • 7.5.3.3 Competitive Scenario
      • 7.5.3.4 Regulatory Framework
      • 7.5.3.5 Reimbursement Scenario
      • 7.5.3.6 Saudi Arabia Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4 UAE
      • 7.5.4.1 Key Country Dynamics
      • 7.5.4.2 Target Disease Prevalence
      • 7.5.4.3 Competitive Scenario
      • 7.5.4.4 Regulatory Framework
      • 7.5.4.5 Reimbursement Scenario
      • 7.5.4.6 UAE Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5 Kuwait
      • 7.5.5.1 Key Country Dynamics
      • 7.5.5.2 Target Disease Prevalence
      • 7.5.5.3 Competitive Scenario
      • 7.5.5.4 Regulatory Framework
      • 7.5.5.5 Reimbursement Scenario
      • 7.5.5.6 Kuwait Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6 Rest of MEA Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8 Infertility Drugs Market: Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants
    • 8.1.1 New Product Launch
    • 8.1.2 Merger and Acquisition
    • 8.1.3 Licensing Agreements
    • 8.1.4 Conferences and Campaigns
  • 8.2 Company Categorization
    • 8.2.1 Innovators
    • 8.2.2 Market Leaders
  • 8.3 Vendor Landscape
    • 8.3.1 List of Key Distributors and Channel Partners
    • 8.3.2 Key Customers
  • 8.4 Public Companies
    • 8.4.1 Key Company Market Share Analysis, 2021
    • 8.4.2 Company Market Position Analysis
    • 8.4.3 Heat Map Analysis
    • 8.4.4 Competitive Dashboard Analysis
      • 8.4.4.1 Market Differentiators
  • 8.5 Private Companies
    • 8.5.1 List of Key Emerging Companies
    • 8.5.2 Regional Network Map
  • 8.6 Company Profiles
      • 8.6.1.Bayer AG
      • 8.6.1.1 Company Overview
      • 8.6.1.2 Financial Performance
      • 8.6.1.3 Product Benchmarking
      • 8.6.1.4 Strategic Initiatives
    • 8.6.2 Novartis AG
      • 8.6.2.1 Company Overview
      • 8.6.2.2 Financial Performance
      • 8.6.2.3 Product Benchmarking
      • 8.6.2.4 Strategic Initiatives
    • 8.6.3 Merck & Co., Inc.
      • 8.6.3.1 Company Overview
      • 8.6.3.2 Financial Performance
      • 8.6.3.3 Product Benchmarking
      • 8.6.3.4 Strategic Initiatives
    • 8.6.4 Ferring B.V.
      • 8.6.4.1 Company Overview
      • 8.6.4.2 Financial Performance
      • 8.6.4.3 Product Benchmarking
      • 8.6.4.4 Strategic Initiatives
    • 8.6.5 Pfizer Inc.
      • 8.6.5.1 Company Overview
      • 8.6.5.2 Financial Performance
      • 8.6.5.3 Product Benchmarking
      • 8.6.5.4 Strategic Initiatives
    • 8.6.6 Mankind Pharma
      • 8.6.6.1 Company Overview
      • 8.6.6.2 Financial Performance
      • 8.6.6.3 Product Benchmarking
      • 8.6.6.4 Strategic Initiatives
    • 8.6.7 Teva Pharmaceutical Industries LTD.
      • 8.6.7.1 Company Overview
      • 8.6.7.2 Financial Performance
      • 8.6.7.3 Product Benchmarking
      • 8.6.7.4 Strategic Initiatives
    • 8.6.8 Sanofi
      • 8.6.8.1 Company Overview
      • 8.6.8.2 Financial Performance
      • 8.6.8.3 Product Benchmarking
      • 8.6.8.4 Strategic Initiatives
    • 8.6.9 Abbott
      • 8.6.8.1 Company Overview
      • 8.6.9.2 Financial Performance
      • 8.6.9.3 Product Benchmarking
      • 8.6.9.4 Strategic Initiatives
    • 8.6.10 Organon Group of Countries
      • 8.6.10.1 Company Overview
      • 8.6.10.2 Product Benchmarking
      • 8.6.10.3 Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Regulatory Framework
  • Table 4 Global Infertility Drugs Market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 6 Global Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 7 Global Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 8 North America Infertility Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 9 North America Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 10 North America Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 11 North America Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 12 U.S. Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 13 U.S. Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 14 U.S. Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 15 Canada Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 16 Canada Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 17 Canada Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 18 Europe Infertility Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 19 Europe Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 20 Europe Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 21 Europe Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 22 Germany Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 23 Germany Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 24 Germany Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 25 UK Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 26 UK Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 27 UK Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 28 France Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 29 France Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 30 France Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 31 Italy Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 32 Italy Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 33 Italy Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 34 Spain Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 35 Spain Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 36 Spain Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 37 Denmark Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 38 Denmark Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 39 Denmark Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 Sweden Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 41 Sweden Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 42 Sweden Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43 Norway Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 44 Norway Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 45 Norway Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Infertility Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 50 Japan Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 51 Japan Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 52 Japan Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 53 China Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 54 China Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 55 China Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 India Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 57 India Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 58 India Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 59 South Korea Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 60 South Korea Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 61 South Korea Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 62 Australia Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 63 Australia Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 64 Australia Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 65 Thailand Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 66 Thailand Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 67 Thailand Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 68 Latin America Infertility Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 69 Latin America Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 70 Latin America Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 71 Latin America Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 72 Brazil Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 73 Brazil Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 74 Brazil Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 75 Mexico Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 76 Mexico Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 77 Mexico Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 78 Argentina Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 79 Argentina Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 80 Argentina Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Infertility Drugs Market, By Country, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 84 Middle East & Africa Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 85 Saudi Arabia Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 88 South Africa Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 89 South Africa Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 90 South Africa Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 91 UAE Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 92 UAE Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 93 UAE Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Infertility Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Infertility Drugs Market, By End-User, 2018 - 2030 (USD Million)
  • Table 96 Kuwait Infertility Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Infertility Drugs Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Data Triangulation Techniques
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value-Chain-Based Sizing & Forecasting
  • Fig. 7 QFD Modeling for Market Share Assessment
  • Fig. 8 Market Formulation & Validation
  • Fig. 9 Commodity Flow Analysis
  • Fig. 10 Market Snapshot (2022) (USD Million)
  • Fig. 11 Segment Snapshot (2022) (USD Million)
  • Fig. 12 Segment Snapshot (2022) (USD Million)
  • Fig. 13 Competitive Snapshot
  • Fig. 14 Penetration and Growth Prospect Mapping
  • Fig. 15 Infertility Drugs Market Driver Impact
  • Fig. 16 Infertility Drugs Market Restraint Impact
  • Fig. 17 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
  • Fig. 18 Porter's Five Forces Analysis
  • Fig. 19 Infertility Drugs Market: Drug Class Outlook and Key Takeaways
  • Fig. 20 Infertility Drugs Market: Drug Class Movement Analysis
  • Fig. 21 Gonadotropins Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Aromatase Inhibitors Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Selective Estrogen Receptor Modulators (SERMs) Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Dopamine Agonists Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Others Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Infertility Drugs Market: Distribution Channe Outlook and Key Takeaways
  • Fig. 27 Infertility Drugs Market: Distribution Channel Movement Analysis
  • Fig. 28 Hospital Pharmacy Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Specialty & Retail Pharmacy Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Online Pharmacy Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Infertility Drugs Market: End-User Outlook and Key Takeaways
  • Fig. 32 Infertility Drugs Market: End-User Movement Analysis
  • Fig. 33 Men Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Women Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Regional Marketplace: Key Takeaways
  • Fig. 36 North America: SWOT analysis
  • Fig. 37 North America Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 U.S. Key Country Dynamics
  • Fig. 39 U.S. Target Disease Prevalence
  • Fig. 40 U.S. Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Canada Key Country Dynamics
  • Fig. 42 Canada Target Disease Prevalence
  • Fig. 43 Canada Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Europe: SWOT analysis
  • Fig. 45 Europe Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Germany Key Country Dynamics
  • Fig. 47 Germany Target Disease Prevalence
  • Fig. 48 Germany Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 UK Key Country Dynamics
  • Fig. 50 UK Target Disease Prevalence
  • Fig. 51 UK Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 France Key Country Dynamics
  • Fig. 53 France Target Disease Prevalence
  • Fig. 54 France Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Italy Key Country Dynamics
  • Fig. 56 Italy Target Disease Prevalence
  • Fig. 57 Italy Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Spain Key Country Dynamics
  • Fig. 59 Spain Target Disease Prevalence
  • Fig. 60 Spain Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Denmark Key Country Dynamics
  • Fig. 62 Denmark Target Disease Prevalence
  • Fig. 63 Denmark Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Sweden Key Country Dynamics
  • Fig. 65 Sweden Target Disease Prevalence
  • Fig. 66 Sweden Infertility Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Norway Key Country Dynamics
  • Fig. 68 Norway Target Disease Prevalence
  • Fig. 69 Norway Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Rest of Europe Infertility Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Asia Pacific: SWOT Analysis
  • Fig. 72 Asia Pacific Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Japan Key Country Dynamics
  • Fig. 74 Japan Target Disease Prevalence
  • Fig. 75 Japan Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 China Key Country Dynamics
  • Fig. 77 China Target Disease Prevalence
  • Fig. 78 China Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 India Key Country Dynamics
  • Fig. 80 India Target Disease Prevalence
  • Fig. 81 India Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Australia Key Country Dynamics
  • Fig. 83 Australia Target Disease Prevalence
  • Fig. 84 Australia Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 South Korea Key Country Dynamics
  • Fig. 86 South Korea Target Disease Prevalence
  • Fig. 87 South Korea Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Thailand Key Country Dynamics
  • Fig. 89 Thailand Target Disease Prevalence
  • Fig. 90 Thailand Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Rest of APAC Infertility Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Latin America (LATAM): SWOT Analysis
  • Fig. 93 Latin America Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Brazil Key Country Dynamics
  • Fig. 95 Brazil Target Disease Prevalence
  • Fig. 96 Brazil Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Mexico Key Country Dynamics
  • Fig. 98 Mexico Target Disease Prevalence
  • Fig. 99 Mexico Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 100 Argentina Key Country Dynamics
  • Fig. 101 Argentina Target Disease Prevalence
  • Fig. 102 Argentina Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Rest of LATAM Infertility Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 104 Middle East & Africa (MEA): SWOT Analysis
  • Fig. 105 Middle East & Africa (MEA) Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 South Africa Key Country Dynamics
  • Fig. 107 Target Disease Prevalence
  • Fig. 108 South Africa Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 Saudi Arabia Key country dynamics
  • Fig. 110 Saudi Arabia Target Disease Prevalence
  • Fig. 111 Saudi Arabia Infertility Drugs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 112 UAE Key Country Dynamics
  • Fig. 113 UAE Target Disease Prevalence
  • Fig. 114 UAE Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 115 Kuwait Key Country Dynamics
  • Fig. 116 Kuwait Target Disease Prevalence
  • Fig. 117 Kuwait Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 118 Rest of MEA Infertility Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 119 Heat Map Analysis
  • Fig. 120 Strategic Framework